A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs . EU-trastuzumab and US-trastuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs . EU-trastuzumab and US-trastuzumab

Published:2018-07-31 Issue:10 Volume:84 Page:2336-2343
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Waller Cornelius F.¹,Vutikullird Apinya²,Lawrence Tracey E.³,Shaw Andrew³,Liu Mark Shiyao³,Baczkowski Mark³,Sharma Rajiv⁴,Barve Abhijit⁵,Goyal Parag⁶,Donnelly Charles³,Sengupta Nilanjan⁷,Pennella Eduardo J.⁵

Affiliation:

1. Department of Haematology, Oncology and Stem Cell Transplantation; University Medical Centre Freiburg, and Faculty of Medicine, University of Freiburg; Freiburg Germany

2. WCCT Global; Cypress CA USA

3. Mylan Inc; Morgantown WV USA

4. Mylan Inc; Hatfield UK

5. Mylan Inc; Canonsburg PA USA

6. Mylan Pharmaceuticals Private Limited; Hyderabad India

7. Biocon Research Ltd; Bangalore India

Funder

Biocon Research Ltd

Mylan Inc

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13689/fullpdf

Reference30 articles.

1. Monoclonal antibodies and Fc fragments for treating solid tumors;Eisenbeis;Biol Targets Ther,2012

2. Monoclonal antibodies in gynecological cancer: a critical point of view;Bellati;Clin Dev Immunol,2011

3. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates;Sharkey;CA Cancer J Clin,2006

4. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications;Iqbal;Mol Biol Int,2014

5. The distinctive nature of HER2-positive breast cancers;Burstein;N Engl J Med,2005

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study;Oncology and Therapy;2024-07-07

2. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study;Scientific Reports;2024-06-04

3. A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin®) in Healthy Chinese Adults;European Journal of Drug Metabolism and Pharmacokinetics;2024-04-02

4. What Powers Trastuzumab's Cardiotoxicity? Decoding Mitochondrial-Related Gene Expression Through Integrative Review and Meta-Analysis in Cardiomyocytes;OMICS: A Journal of Integrative Biology;2024-03-01

5. Biosimilar in Cervical Cancer;Biosimilars for Cancer Treatment;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3